Biopharmaceutical / Specialty Pharmaceuticals - Organ Fibrosis Therapeutics & Oncology
Strategic Profile
The recent Cullgen acquisition will create a U.S.- and China-based fully integrated biopharmaceutical company with revenue-producing commercial assets and a robust pipeline. Cullgen brings strong drug discovery capabilities and a solid preclinical and clinical pipeline to complement Gyre's existing and highly efficient China-based manufacturing capabilities and sales team. This strategic combination positions Gyre to leverage dual geographic strengths and expand beyond organ fibrosis into oncology and pain indications.
Cyborg Score Rationale
Gyre Pharmaceuticals' flagship product ETUARY (pirfenidone) was the first approved treatment for IPF in the PRC in 2011 and has maintained prominent market share with 2024 net sales of $105.8 million. Gyre Pharmaceuticals plans to submit an NDA for Hydronidone for conditional approval in the first half of 2026. The Cullgen acquisition adds a transformative platform, though regulatory and integration execution risks remain.
Top Insights
Gyre is acquiring Cullgen in an all-stock deal valuing Cullgen at approximately $300 million, bringing a targeted protein degradation and degrader antibody conjugate platform into Gyre's portfolio.
As of the third quarter of 2025, Gyre Therapeutics owns a 69.7% equity interest in Gyre Pharmaceuticals.
China's CDE supported conditional approval and priority review eligibility filing for Hydronidone, with NDA submission planned for the first half of 2026.
Pipeline includes ETUARY in Phase 3 for pneumoconiosis, Hydronidone in Phase 3 for liver fibrosis, and F573 in Phase 2 for acute liver failure.
Named Competitors
Pirfenidone (generic/other brands) — Anti-fibrotic for IPF, direct competitor to ETUARY
Nintedanib — Tyrosine kinase inhibitor for IPF and related fibrotic diseases
Targeted Protein Degradation Platforms — Competitive positioning in emerging oncology and pain indications
Recent Developments
(March 2026) Announced $300M all-stock acquisition of Cullgen Inc. to gain targeted protein degradation platform
(March 2026) China CDE approved conditional approval and priority review eligibility pathway for Hydronidone
(Q3 2025) Reported third quarter 2025 financial results with ongoing Phase 3 programs
Open the full interactive Gyre Therapeutics, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.